ACM
KALV

Asymmetry Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Asymmetry Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-46,910
Closed -$891K – 36
2020
Q4 		$891K Buy
+46,910
New +$804K 0.41% 33

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Asymmetry Capital Management's KALV Position: Q1 2021 in Review

Asymmetry Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2021, closing a stake of 46,910 shares — an estimated $891K sold.

Asymmetry Capital Management first reported a position in KALV in Q4 2020 and held it in 1 quarter. The position peaked at $891K in Q4 2020. 117 funds tracked by Wall St. Rank hold KALV as of Q1 2021.

  • Asymmetry Capital Management reported no remaining KalVista Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 46,910 KalVista Pharmaceuticals shares in Q1 2021, an estimated $891K.
  • Asymmetry Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Asymmetry Capital Management's KalVista Pharmaceuticals position peaked at $891K in Q4 2020.
  • 117 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2021.

Based on Asymmetry Capital Management's 13F filing for Q1 2021, filed 11 May 2021.